Insulet (PODD) Stock Forecast & Price Target

Compare

1,012 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PODD Analyst Ratings

Strong Buy

16 Buy

1 Hold

1 Sell

Based on 18 analysts giving stock ratings to

Insulet

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PODD Stock 12 Month Forecast

Average Price Target

$368.41

▲(50.02% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $368.41 with a high forecast of $450.00 and a low forecast of $274.00. The average price target represents a 50.02% change from the last price of $245.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"249":"$249","350":"$350","451":"$451","299.5":"$299.5","400.5":"$400.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":450,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$450.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":368.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$368.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":274,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$274.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[249,299.5,350,400.5,451],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.62,271.49538461538464,286.3707692307692,301.24615384615385,316.1215384615385,330.99692307692305,345.8723076923077,360.7476923076923,375.62307692307695,390.4984615384615,405.37384615384616,420.24923076923073,435.12461538461537,{"y":450,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.62,265.21923076923076,273.8184615384615,282.41769230769233,291.0169230769231,299.61615384615385,308.2153846153846,316.8146153846154,325.4138461538462,334.01307692307694,342.6123076923077,351.21153846153845,359.8107692307692,{"y":368.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.62,257.9569230769231,259.2938461538462,260.63076923076926,261.9676923076923,263.3046153846154,264.64153846153846,265.97846153846154,267.31538461538463,268.6523076923077,269.98923076923074,271.32615384615383,272.6630769230769,{"y":274,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":278.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":344.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.83,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$450.00

Average Price Target$368.41

Lowest Price Target$274.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathan Block

Stifel Nicolaus

$370→$350

Buy

42.53%

Upside

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Chugai Pharmaceutical Co (Other OTC: CHGCF), Medtronic (NYSE: MDT) and Insulet (NASDAQ: PODD)

Marie Thibault

BTIG

$380

Buy

54.74%

Upside

Reiterated

02/03/26

BTIG Keeps Their Buy Rating on Insulet (PODD)

Mathew Blackman

TD Cowen

$379→$294

Hold

19.72%

Upside

Downgraded

01/27/26

Balanced Risk–Reward for Insulet: Strong Growth but Rising Competition Justifies Hold Rating and $294 Target

Shagun Singh Chadha

RBC Capital

$380

Buy

54.74%

Upside

Reiterated

01/20/26

Analysts Conflicted on These Healthcare Names: Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)

Larry Biegelsen

Wells Fargo

$360

Buy

46.60%

Upside

Reiterated

01/13/26

Wells Fargo Sticks to Their Buy Rating for Insulet (PODD)

Lee Hambright

Bernstein

$380

Buy

54.74%

Upside

Reiterated

01/13/26

Insulet (PODD) Receives a Buy from Bernstein

William Plovanic

Canaccord Genuity

$450

Buy

83.25%

Upside

Reiterated

01/12/26

Matt Miksic

Barclays

$316→$274

Sell

11.58%

Upside

Downgraded

01/09/26

Insulet downgraded to Underweight from Equal Weight at BarclaysInsulet downgraded to Underweight from Equal Weight at Barclays

David Roman

Goldman Sachs

$388→$365

Buy

48.63%

Upside

Reiterated

01/09/26

Insulet price target lowered to $365 from $388 at Goldman SachsInsulet price target lowered to $365 from $388 at Goldman Sachs

Richard Newitter

Truist Financial

$412→$390

Buy

58.81%

Upside

Reiterated

12/18/25

Insulet price target lowered to $390 from $412 at TruistInsulet price target lowered to $390 from $412 at Truist

Danielle Antalffy

UBS

$400

Buy

62.89%

Upside

Reiterated

12/18/25

Analysts' Top Healthcare Picks: AxoGen (AXGN), Irhythm Technologies (IRTC)

Daniel Markowitz CFA

Evercore ISI

$370

Buy

50.67%

Upside

Initiated

12/17/25

Insulet initiated with an Outperform at Evercore ISIInsulet initiated with an Outperform at Evercore ISI

Jeff Johnson

Robert W. Baird

$360

Buy

46.60%

Upside

Reiterated

12/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

$380

Buy

54.74%

Upside

Reiterated

12/11/25

Citi Reaffirms Their Buy Rating on Insulet (PODD)

Patrick Wood

Morgan Stanley

$370

Buy

50.67%

Upside

Reiterated

12/04/25

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathan Block

Stifel Nicolaus

$370→$350

Buy

42.53%

Upside

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Chugai Pharmaceutical Co (Other OTC: CHGCF), Medtronic (NYSE: MDT) and Insulet (NASDAQ: PODD)

Marie Thibault

BTIG

$380

Buy

54.74%

Upside

Reiterated

02/03/26

BTIG Keeps Their Buy Rating on Insulet (PODD)

Mathew Blackman

TD Cowen

$379→$294

Hold

19.72%

Upside

Downgraded

01/27/26

Balanced Risk–Reward for Insulet: Strong Growth but Rising Competition Justifies Hold Rating and $294 Target

Shagun Singh Chadha

RBC Capital

$380

Buy

54.74%

Upside

Reiterated

01/20/26

Analysts Conflicted on These Healthcare Names: Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)

Larry Biegelsen

Wells Fargo

$360

Buy

46.60%

Upside

Reiterated

01/13/26

Wells Fargo Sticks to Their Buy Rating for Insulet (PODD)

Lee Hambright

Bernstein

$380

Buy

54.74%

Upside

Reiterated

01/13/26

Insulet (PODD) Receives a Buy from Bernstein

William Plovanic

Canaccord Genuity

$450

Buy

83.25%

Upside

Reiterated

01/12/26

Matt Miksic

Barclays

$316→$274

Sell

11.58%

Upside

Downgraded

01/09/26

Insulet downgraded to Underweight from Equal Weight at BarclaysInsulet downgraded to Underweight from Equal Weight at Barclays

David Roman

Goldman Sachs

$388→$365

Buy

48.63%

Upside

Reiterated

01/09/26

Insulet price target lowered to $365 from $388 at Goldman SachsInsulet price target lowered to $365 from $388 at Goldman Sachs

Richard Newitter

Truist Financial

$412→$390

Buy

58.81%

Upside

Reiterated

12/18/25

Insulet price target lowered to $390 from $412 at TruistInsulet price target lowered to $390 from $412 at Truist

Danielle Antalffy

UBS

$400

Buy

62.89%

Upside

Reiterated

12/18/25

Analysts' Top Healthcare Picks: AxoGen (AXGN), Irhythm Technologies (IRTC)

Daniel Markowitz CFA

Evercore ISI

$370

Buy

50.67%

Upside

Initiated

12/17/25

Insulet initiated with an Outperform at Evercore ISIInsulet initiated with an Outperform at Evercore ISI

Jeff Johnson

Robert W. Baird

$360

Buy

46.60%

Upside

Reiterated

12/16/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

$380

Buy

54.74%

Upside

Reiterated

12/11/25

Citi Reaffirms Their Buy Rating on Insulet (PODD)

Patrick Wood

Morgan Stanley

$370

Buy

50.67%

Upside

Reiterated

12/04/25

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insulet

3 Months

xxx

Success Rate

16/18 ratings generated profit

Average Return

+12.17%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +12.17% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

19/25 ratings generated profit

Average Return

+27.54%

reiterated a buy rating 2 months ago

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +27.54% per trade.

2 Years

xxx

Success Rate

23/25 ratings generated profit

Average Return

+72.13%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.00% of your transactions generating a profit, with an average return of +72.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PODD Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PODD has received 33 Buy Ratings, 11 Hold Ratings, and 1 Sell Ratings. PODD average Analyst price target in the past 3 months is 368.41.

Each month's total comprises the sum of three months' worth of ratings.

PODD Financial Forecast

PODD Earnings Forecast

Next quarter’s earnings estimate for PODD is $1.46 with a range of $1.32 to $1.86. The previous quarter’s EPS was $1.24. PODD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Sales Forecast

Next quarter’s sales forecast for PODD is $768.97M with a range of $761.20M to $778.00M. The previous quarter’s sales results were $706.30M. PODD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year PODD has Performed in-line its overall industry.

PODD Stock Forecast FAQ

What is PODD’s average 12-month price target, according to analysts?

Based on analyst ratings, Insulet’s 12-month average price target is 368.41.

What is PODD’s upside potential, based on the analysts’ average price target?

Insulet has 50.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PODD a Buy, Sell or Hold?

Insulet has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 1 sell ratings.

What is Insulet’s price target?

The average price target for Insulet is 368.41. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $450.00 ,the lowest forecast is $274.00. The average price target represents 50.02% Increase from the current price of $245.57.

What do analysts say about Insulet?

Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of PODD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Insulet (PODD) Stock Forecast & Price Target

PODD Analyst Ratings

PODD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insulet

PODD Analyst Recommendation Trends

PODD Financial Forecast

PODD Earnings Forecast

PODD Sales Forecast

PODD Stock Forecast FAQ

Detailed List of Analyst Forecasts